Prospective Study Examining Remote Effects of Botulinum Toxin A in Children With Cerebral Palsy

Pediatric Neurology

Volumn 39, Issue 4, 2008, Pages 253-258

  Crowner, Beth E ^a   Racette, Brad A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADOLESCENT; ARM MUSCLE; ARTICLE; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DYNAMOMETRY; ELBOW; FEMALE; FINGER; FLEXOR MUSCLE; FUNCTIONAL ASSESSMENT; GRIP STRENGTH; HEMIPLEGIA; HUMAN; LEG MUSCLE; LOW DRUG DOSE; MALE; MOEBIUS SYNDROME; MUSCLE FUNCTION; MUSCLE STRENGTH; PRIORITY JOURNAL; PROSPECTIVE STUDY; SHOULDER; SINGLE BLIND PROCEDURE; SPASTICITY; WEAKNESS;

ADOLESCENT; BOTULINUM TOXIN TYPE A; BRAIN DAMAGE, CHRONIC; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; LOWER EXTREMITY; MALE; MOTOR SKILLS; MUSCLE SPASTICITY; MUSCLE STRENGTH; MUSCLE, SKELETAL; NEUROLOGIC EXAMINATION; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; UPPER EXTREMITY;

EID: 52049103123     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2008.07.003     Document Type: Article

References (58)

1. Himmelmann K., Hagberg G., Beckung E., Hagberg B., and Uvebrant P. The changing panorama of cerebral palsy in Sweden. IX. Prevalence and origin in the birth-year period 1995-1998. Acta Paediatr Scand 94 (2005) 287-294
2. Hagberg B., Hagberg G., Beckung E., and Uvebrant P. Changing panorama of cerebral palsy in Sweden. VIII. Prevalence and origin in the birth year period 1991-94. Acta Paediatr Scand 90 (2001) 271-277
3. Stanley F.J., and Watson L. Trends in perinatal mortality and cerebral palsy in Western Australia, 1967 to 1985. Br Med J [Clin Res] 304 (1992) 1658-1663
4. Robertson C.M., Svenson L.W., and Joffres M.R. Prevalence of cerebral palsy in Alberta. Can J Neurol Sci 25 (1998) 117-122
5. Marlow N., Wolke D., Bracewell M.A., and Samara M. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 352 (2005) 9-19
6. Scheinberg A., Hall K., Lam L.T., and O'Flaherty S. Oral baclofen in children with cerebral palsy: A double-blind cross-over pilot study. J Paediatr Child Health 42 (2006) 715-720
7. Desloovere K., Molenaers G., De C.J., et al. Motor function following multilevel botulinum toxin type A treatment in children with cerebral palsy. Dev Med Child Neurol 49 (2007) 56-61
8. Campbell W.M., Ferrel A., McLaughlin J.F., et al. Long-term safety and efficacy of continuous intrathecal baclofen. Dev Med Child Neurol 44 (2002) 660-665
9. Berweck S., and Heinen F. Use of botulinum toxin in pediatric spasticity (cerebral palsy). Mov Disord 19 Suppl. 8 (2004) S162-S167
10. Kirschner J., Berweck S., Mall V., Korinthenberg R., and Heinen F. Botulinum toxin treatment in cerebral palsy: Evidence for a new treatment option. J Neurol 248 Suppl. 1 (2001) 28-30
11. Bakheit A.M., Severa S., Cosgrove A., et al. Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Dev Med Child Neurol 43 (2001) 234-238
12. Wissel J., Heinen F., Schenkel A., et al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: A randomized, double-blind study of "high-dose" versus "low-dose" treatment. Neuropediatrics 30 (1999) 120-124
13. Wong V. Use of botulinum toxin injection in 17 children with spastic cerebral palsy. Pediatr Neurol 18 (1998) 124-131
14. Love S.C., Valentine J.P., Blair E.M., Price C.J., Cole J.H., and Chauvel P.J. The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia: A randomized controlled trial. Eur J Neurol 8 Suppl. 5 (2001) 50-58
15. Linder M., Schindler G., Michaelis U., et al. Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1-year follow-up using gross motor function measure. Eur J Neurol 8 Suppl. 5 (2001) 120-126
16. Slawek J., and Klimont L. Functional improvement in cerebral palsy patients treated with botulinum toxin A injections-Preliminary results. Eur J Neurol 10 (2003) 313-317
17. Ubhi T., Bhakta B.B., Ives H.L., Allgar V., and Roussounis S.H. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 83 (2000) 481-487
18. Corry I.S., Cosgrove A.P., Duffy C.M., McNeill S., Taylor T.C., and Graham H.K. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: A randomised prospective trial. J Pediatr Orthop 18 (1998) 304-311
19. Metaxiotis D., Siebel A., and Doederlein L. Repeated botulinum toxin A injections in the treatment of spastic equinus foot. Clin Orthop 394 (2002) 177-185
20. Koman L.A., Brashear A., Rosenfeld S., et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: A multicenter, open-label clinical trial. Pediatrics 108 (2001) 1062-1071
21. Brin M.F. Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 6 Suppl. (1997) S146-S168
22. Koman L.A., Mooney III J.F., Smith B.P., Goodman A., and Mulvaney T. Management of spasticity in cerebral palsy with botulinum-A toxin: Report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 14 (1994) 299-303
23. Heinen F., Schroeder A.S., Fietzek U., and Berweck S. When it comes to botulinum toxin, children and adults are not the same: Multimuscle option for children with cerebral palsy. Mov Disord 21 (2006) 2029-2030
24. Gelb D.J., Lowenstein D.H., and Aminoff M.J. Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology 39 (1989) 80-84
25. Brashear A., Truong D., Charles D., Comella C., Hauser R.A., and Tsui J. A randomized double-blind placebo-controlled study of intramuscular Botox for the treatment of cervical dystonia (CD). Mov Disord 13 (1998) 276
26. Scott A.B., and Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 3 (1988) 333-335
27. Olney R.K., Aminoff M.J., Gelb D.J., and Lowenstein D.H. Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 38 (1988) 1780-1783
28. Lange D.J., Brin M.F., Warner C.L., Fahn S., and Lovelace R.E. Distant effects of local injection of botulinum toxin. Muscle Nerve 10 (1987) 552-555
29. Sanders D.B., Massey E.W., and Buckley E.G. Botulinum toxin for blepharospasm: Single-fiber EMG studies. Neurology 36 (1986) 545-547
30. Girlanda P., Vita G., Nicolosi C., Milone S., and Messina C. Botulinum toxin therapy: Distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 55 (1992) 844-845
31. Garner C.G., Straube A., Witt T.N., Gasser T., and Oertel W.H. Time course of distant effects of local injections of botulinum toxin. Mov Disord 8 (1993) 33-37
32. Bakheit A.M., Ward C.D., and McLellan D.L. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: A report of two cases. J Neurol Neurosurg Psychiatry 62 (1997) 198
33. Bhatia K.P., Munchau A., Thompson P.D., et al. Generalised muscular weakness after botulinum toxin injections for dystonia: A report of three cases. J Neurol Neurosurg Psychiatry 67 (1999) 90-93
34. Goldstein E.M. Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol 21 (2006) 189-192
35. Public Citizen 2008. Available at: http://www.citizen.org/publications/release.cfm?ID=7559.
36. Food and Drug Administration (2007). http://www.fda.gov/medwatch/index.html
37. Oeffinger D.J., Tylkowski C.M., Rayens M.K., et al. Gross Motor Function Classification System and outcome tools for assessing ambulatory cerebral palsy: A multicenter study. Dev Med Child Neurol 46 (2004) 311-319
38. Criswell S.R., Crowner B.E., and Racette B.A. The use of botulinum toxin therapy for lower-extremity spasticity in children with cerebral palsy. Neurosurg Focus 21 (2006) e1
39. Jankovic J., and Schwartz K.S. Clinical correlates of response to botulinum toxin injections. Arch Neurol 48 (1991) 1253-1256
40. Sloan C. Review of the reliability and validity of myometry with children. Phys Occup Ther Pediatr 22 (2002) 79-93
41. Daltroy L.H., Liang M.H., Fossel A.H., and Goldberg M.J. The POSNA pediatric musculoskeletal functional health questionnaire: Report on reliability, validity, and sensitivity to change. Pediatric Outcomes Instrument Development Group. Pediatric Orthopaedic Society of North America. J Pediatr Orthop 18 (1998) 561-571
42. Bohannon R.W., and Smith M.B. Interrater reliability of a Modified Ashworth Scale of muscle spasticity. Phys Ther 67 (1987) 206-207
43. Skogseid I.M., and Kerty E. The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol 12 (2005) 163-170
44. Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord 19 Suppl. 8 (2004) S109-S115
45. Taylor N.F., Dodd K.J., and Graham H.K. Test-retest reliability of hand-held dynamometric strength testing in young people with cerebral palsy. Arch Phys Med Rehabil 85 (2004) 77-80
46. Berry E.T., Giuliani C.A., and Damiano D.L. Intrasession and intersession reliability of handheld dynamometry in children with cerebral palsy. Pediatr Phys Ther 16 (2004) 191-198
47. Crompton J., Galea M.P., and Phillips B. Hand-held dynamometry for muscle strength measurement in children with cerebral palsy. Dev Med Child Neurol 49 (2007) 106-111
48. Florence J.M., Pandya S., King W.M., et al. Intrarater reliability of manual muscle test (Medical Research Council scale) grades in Duchenne's muscular dystrophy. Phys Ther 72 (1992) 115-122
49. McCarthy M.L., Silberstein C.E., Atkins E.A., Harryman S.E., Sponseller P.D., and Hadley-Miller N.A. Comparing reliability and validity of pediatric instruments for measuring health and well-being of children with spastic cerebral palsy. Dev Med Child Neurol 44 (2002) 468-476
50. Tervo R.C., Azuma S., Stout J., and Novacheck T. Correlation between physical functioning and gait measures in children with cerebral palsy. Dev Med Child Neurol 44 (2002) 185-190
51. Reddihough D.S., King J.A., Coleman G.J., et al. Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy. Dev Med Child Neurol 44 (2002) 820-827
52. Suputtitada A. Managing spasticity in pediatric cerebral palsy using a very low dose of botulinum toxin type A: Preliminary report. Am J Phys Med Rehabil 79 (2000) 320-326
53. Fragala M., O'Neal M., Russo K., and Dumas H. Impairment, disability, and satisfaction outcomes after lower extremity botulinum toxin A injections for children with cerebral palsy. Pediatr Phys Ther 14 (2002) 132-144
54. Gracies J.M., Marosszeky J.E., Renton R., Sandanam J., Gandevia S.C., and Burke D. Short-term effects of dynamic Lycra splints on upper limb in hemiplegic patients. Arch Phys Med Rehabil 81 (2000) 1547-1555
55. Boyd R., and Graham K. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol 6 Suppl. 4 (1999) S23-S25
56. Fosang A., Galea M., Reddihough D., and McCoy A. Inter-rater and intra-rater reliability of three measures of spasticity in the lower limb. Dev Med Child Neurol 88 Suppl. (2001) 25-26
57. Fosang A.L., Galea M.P., McCoy A.T., Reddihough D.S., and Story I. Measures of muscle and joint performance in the lower limb of children with cerebral palsy. Dev Med Child Neurol 45 (2003) 664-670
58. Palisano R., Rosenbaum P., Walter S., Russell D., Wood E., and Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 39 (1997) 214-223